Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study
Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX®‐i120 platform to facilitate negative enrichment, immunof...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-09-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.12876 |
| _version_ | 1831748504023728128 |
|---|---|
| author | Peng‐Xiang Wang Yun‐Fan Sun Wei‐Xiang Jin Jian‐Wen Cheng Hai‐Xiang Peng Yang Xu Kai‐Qian Zhou Li‐Meng Chen Kai Huang Sui‐Yi Wu Bo Hu Ze‐Fan Zhang Wei Guo Ya Cao Jian Zhou Jia Fan Xin‐Rong Yang |
| author_facet | Peng‐Xiang Wang Yun‐Fan Sun Wei‐Xiang Jin Jian‐Wen Cheng Hai‐Xiang Peng Yang Xu Kai‐Qian Zhou Li‐Meng Chen Kai Huang Sui‐Yi Wu Bo Hu Ze‐Fan Zhang Wei Guo Ya Cao Jian Zhou Jia Fan Xin‐Rong Yang |
| author_sort | Peng‐Xiang Wang |
| collection | DOAJ |
| description | Circulating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX®‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX®‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX®‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P < 0.05). Single‐cell sequencing analysis revealed that heterogeneous genomic alteration patterns resided in different cells, patients, and cancers. Our results suggest that the use of this ChimeraX®‐i120 platform and the integrated workflow has validity as a tool for CTC detection and downstream genomic profiling in the clinical setting. |
| first_indexed | 2024-12-21T21:52:52Z |
| format | Article |
| id | doaj.art-0404e2d999594741806a47d454e262e2 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-12-21T21:52:52Z |
| publishDate | 2021-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-0404e2d999594741806a47d454e262e22022-12-21T18:49:03ZengWileyMolecular Oncology1574-78911878-02612021-09-011592345236210.1002/1878-0261.12876Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective studyPeng‐Xiang Wang0Yun‐Fan Sun1Wei‐Xiang Jin2Jian‐Wen Cheng3Hai‐Xiang Peng4Yang Xu5Kai‐Qian Zhou6Li‐Meng Chen7Kai Huang8Sui‐Yi Wu9Bo Hu10Ze‐Fan Zhang11Wei Guo12Ya Cao13Jian Zhou14Jia Fan15Xin‐Rong Yang16Department of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaShanghai Epione Medlab ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaShanghai Epione Medlab ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaShanghai Epione Medlab ChinaShanghai Epione Medlab ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Laboratory Medicine Zhongshan Hospital Fudan University Shanghai ChinaKey Laboratory of Carcinogenesis and Cancer Invasion Cancer Research Institute Central South University Ministry of Education Changsha ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaDepartment of Liver Surgery & Transplantation Liver Cancer Institute Zhongshan Hospital Fudan University Shanghai ChinaCirculating tumor cell (CTC) analysis holds great potential to be a noninvasive solution for clinical cancer management. A complete workflow that combined CTC detection and single‐cell molecular analysis is required. We developed the ChimeraX®‐i120 platform to facilitate negative enrichment, immunofluorescent labeling, and machine learning‐based identification of CTCs. Analytical performances were evaluated, and a total of 477 participants were enrolled to validate the clinical feasibility of ChimeraX®‐i120 CTC detection. We analyzed copy number alteration profiles of isolated single cells. The ChimeraX®‐i120 platform had high sensitivity, accuracy, and reproducibility for CTC detection. In clinical samples, an average value of > 60% CTC‐positive rate was found for five cancer types (i.e., liver, biliary duct, breast, colorectal, and lung), while CTCs were rarely identified in blood from healthy donors. In hepatocellular carcinoma patients treated with curative resection, CTC status was significantly associated with tumor characteristics, prognosis, and treatment response (all P < 0.05). Single‐cell sequencing analysis revealed that heterogeneous genomic alteration patterns resided in different cells, patients, and cancers. Our results suggest that the use of this ChimeraX®‐i120 platform and the integrated workflow has validity as a tool for CTC detection and downstream genomic profiling in the clinical setting.https://doi.org/10.1002/1878-0261.12876circulating tumor cellenumerationintegrated platformliquid biopsymachine learning‐based image recognitionsingle‐cell sequencing |
| spellingShingle | Peng‐Xiang Wang Yun‐Fan Sun Wei‐Xiang Jin Jian‐Wen Cheng Hai‐Xiang Peng Yang Xu Kai‐Qian Zhou Li‐Meng Chen Kai Huang Sui‐Yi Wu Bo Hu Ze‐Fan Zhang Wei Guo Ya Cao Jian Zhou Jia Fan Xin‐Rong Yang Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study Molecular Oncology circulating tumor cell enumeration integrated platform liquid biopsy machine learning‐based image recognition single‐cell sequencing |
| title | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study |
| title_full | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study |
| title_fullStr | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study |
| title_full_unstemmed | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study |
| title_short | Circulating tumor cell detection and single‐cell analysis using an integrated workflow based on ChimeraX®‐i120 Platform: A prospective study |
| title_sort | circulating tumor cell detection and single cell analysis using an integrated workflow based on chimerax r i120 platform a prospective study |
| topic | circulating tumor cell enumeration integrated platform liquid biopsy machine learning‐based image recognition single‐cell sequencing |
| url | https://doi.org/10.1002/1878-0261.12876 |
| work_keys_str_mv | AT pengxiangwang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT yunfansun circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT weixiangjin circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT jianwencheng circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT haixiangpeng circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT yangxu circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT kaiqianzhou circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT limengchen circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT kaihuang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT suiyiwu circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT bohu circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT zefanzhang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT weiguo circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT yacao circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT jianzhou circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT jiafan circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy AT xinrongyang circulatingtumorcelldetectionandsinglecellanalysisusinganintegratedworkflowbasedonchimeraxi120platformaprospectivestudy |